Key facts
- Ranok Therapeutics announced positive interim Phase 1 data for its KRAS G12D inhibitor RNK08954.
- The data pertains to patients with KRAS G12D-mutated metastatic non-small cell lung cancer.
- The findings were presented at ASCO 2026.
This announcement provides an update on the clinical trial progress of Ranok Therapeutics' drug candidate, RNK08954, which targets a specific mutation in non-small cell lung cancer. Positive interim data suggests potential efficacy and safety, which could influence investor sentiment and future development.
